fashion -WSS

fashion

author：entertainment 2025-09-07 21:53:57 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How Medicaid coverage policies for immigrants impact new moms

explore

WSS

Juul documents reveal insider tactics on political lobbying

WHO calls for emergency meeting on new China virus, as cases spread

Listen: Wegovy in the brain & pivotal Alzheimer's data

Long Covid research funding gets a major boost from NIH

How dance can help nurses traumatized by Covid

STAT Virtual Event: The State of Biosimilars: What to Watch

hotspot

fashion

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Biden tests positive for Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ebola vaccine can save some who are already sick, per new study

Sports medicine is finally prioritizing gender equality

Group opposing PBM reform sets lobbying record

United colonoscopy coverage change 'may cost lives,' doctors say

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Activists slam private health insurers over coverage restrictions

Study gives hint on South Asians’ higher risk of cardiovascular disease

hotspot

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Sanofi seeks simpler, safer CRISPR sickle cell cure

Study gives hint on South Asians’ higher risk of cardiovascular disease

Ebola vaccine can save some who are already sick, per new study

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Doctors on social media are being harassed and cyberbullied

focus

explore

Wikipedia

explore